10.20USDMkt Cap: 36.84M USDP/E: —Last update: 2026-05-21
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fu…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap36.84M USD
Enterprise Value10.98M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-55.84M USD
Revenue/Share—
Last Price10.20 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS65343E1082
Valuation
P/E (Trailing)—
P/E (Forward)-1.22
PEG—
EV/EBITDA-0.20
EV/Revenue—
P/S—
P/B1.02
EPS (TTM)-16.82
EPS (Forward)-8.35
52W Range
9.12068% of range10.70
52W High10.70 USD
52W Low9.120 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.81%
ROA-111.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.61M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-73.67%
Net Debt-25.86M USD
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity0.15
Current Ratio4.61
Quick Ratio4.32
Book Value/Sh9.968 USD
Cash/Share8.234 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 14, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)19.33 USD
Target Range15.00 USD – 25.00 USD
# Analysts3
Ownership
Shares Out.3.61M
Float2.28M
Insiders14.84%
Institutions62.54%
Short Interest
Short Ratio1.0d
Short % Float2.00%
Short % Out.2.00%
Shares Short72.14K
Short (prev mo.)55.52K
Technical
SMA 5010.61 (-3.8%)
SMA 2009.955 (+2.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)43.44K
Avg Vol (10d)24.14K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—